---
title: "Protara Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286257642.md"
datetime: "2026-05-13T12:07:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286257642.md)
  - [en](https://longbridge.com/en/news/286257642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286257642.md)
---

# Protara Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.31, beating the estimate of USD -0.3693.

EBIT: As of FY2026 Q1, the actual value is USD -21.48 M.

#### Cash and Investments

As of March 31, 2026, unrestricted cash and cash equivalents and marketable debt securities totaled $177.4 million, which is expected to fund planned operations and milestones into 2028.

#### Research and Development Expenses

Research and development expenses for the first quarter of 2026 increased to $13.6 million from $9.1 million for the prior year period. This increase was primarily due to a $2.2 million increase in direct expenses for product candidates and a $2.2 million increase in indirect expenses not directly attributable to one specific product candidate.

#### General and Administrative Expenses

General and administrative expenses for the first quarter of 2026 increased to $6.1 million from $5.0 million for the prior year period. The increase was primarily due to personnel-related expenses, including stock-based compensation.

#### Net Loss

For the first quarter of 2026, Protara Therapeutics, Inc. incurred a net loss of - $17.8 million, compared with a net loss of - $11.9 million for the same period in 2025. Net loss for the first quarter of 2026 included approximately $1.4 million in stock-based compensation expenses.

#### Net Loss Per Share

Net loss per share attributable to common stockholders was - $0.31 for the first quarter of 2026, compared to - $0.29 per share for the same period in 2025.

#### Balance Sheet Highlights (Unaudited)

-   **Total Assets:** $191,923 thousand as of March 31, 2026, down from $209,468 thousand as of December 31, 2025.
-   **Total Liabilities:** $10,715 thousand as of March 31, 2026, down from $13,056 thousand as of December 31, 2025.
-   **Total Stockholders’ Equity:** $181,208 thousand as of March 31, 2026, down from $196,412 thousand as of December 31, 2025.

#### Operational Metrics and Outlook

Protara Therapeutics, Inc. intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in the second half of 2027. The company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in the second half of 2026. Additionally, interim results for the THRIVE-3 program for IV Choline Chloride are expected to be announced in the second half of 2026.

### Related Stocks

- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)

## Related News & Research

- [Protara Therapeutics Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295534784.md)
- [Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26](https://longbridge.com/en/news/295589045.md)
- [Apple declares Q3 2026 distribution of R$ 0.05 per unit, payable Aug. 19](https://longbridge.com/en/news/296137926.md)
- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 3](https://longbridge.com/en/news/295953690.md)
- [2Invest AG schedules release of half-year 2026 report](https://longbridge.com/en/news/295943641.md)